This article first appeared on GuruFocus.

Revenue from Operations: Increased by 13.9% to INR71.81 crore.

Total Income: Grew by 14.4% to INR76.72 crore.

EBITDA: Increased by 13.3% to INR29.62 crore.

Profit Before Tax (PBT): Grew by 13.9% to INR27.61 crore.

Profit After Tax (PAT): Increased by 12.9% to INR20.49 crore.

EBITDA Margin: 38.6%.

PBT Margin: 36.0%.

PAT Margin: 26.7%.

Domestic Business Growth: 9%.

Export Business Growth: 17.58%.

Q4 Revenue from Operations: Increased by 2.63% to INR8.94 crore.

Q4 Total Income: Grew by 4.18% to INR20.35 crore.

Q4 EBITDA: Increased by 9.09% to INR8.32 crore.

Q4 Profit Before Tax (PBT): Grew by 9.21% to INR7.81 crore.

Q4 Profit After Tax (PAT): Increased by 13.23% to INR5.82 crore.

Q4 EBITDA Margin: Improved to 40.87%.

Q4 PBT Margin: 38.38%.

Q4 PAT Margin: 28.61%.

Release Date: June 29, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Prevest Denpro Ltd (BOM:543363) achieved a 13.9% increase in revenue from operations, reaching INR71.81 crore, reflecting broad-based growth across business segments.

The company recorded a strong export growth of 17.58%, demonstrating resilience in international markets despite geopolitical challenges.

The establishment of a wholly-owned subsidiary in the UAE marks a significant step in strengthening the company’s international presence.

Prevest Denpro Ltd (BOM:543363) successfully launched its disinfectant business, aligning with rising demand for hygiene-driven products in dental and medical settings.

The company is making significant progress in digital dentistry, with a focus on developing next-generation digital solutions and 3D printers, which are expected to be major growth drivers.

Negative Points

The global business environment posed challenges, with geopolitical tensions and conflicts disrupting trade and logistics, impacting customer ordering patterns.

The commencement of commercial operations in the UAE subsidiary was delayed due to geopolitical tensions in the Middle East.

The company’s margins moderated slightly compared to the previous year, although they remain strong.

The fourth quarter of 2025-26 was challenging from a revenue perspective due to high geopolitical tensions and disruptions in global shipping and supply chains.

The Oradox business experienced a 2% decline in sales due to export challenges related to new regulatory requirements in the US and geopolitical issues in Dubai.

Q & A Highlights

Q: The company’s growth rate has slowed compared to previous years. What are the reasons for this change? A: Namrata Modi, Co-Founder and CFO, explained that initial growth rates were high due to the company’s early stage. Despite geopolitical challenges, the company achieved a 17-18% growth rate, particularly in exports, which is satisfactory given the current global scenario. The company is optimistic about future growth as it expands its reach across 192 countries.

Q: How much of the company’s revenue is allocated to R&D? A: Dr. Sai Kalyan, Director of Research & Academics, stated that while the exact number wasn’t available, significant progress has been made in product development and regulatory approvals. The company is also working on import substitution and developing new raw materials, which contributes to revenue generation.

Q: Can you elaborate on the purpose of the subsidiaries in Dubai and the US, and the current capacity utilization? A: Namrata Modi explained that the US subsidiary, Accudent, has seen a 37.58% growth, driven by private labeling and direct sales. The Dubai subsidiary, despite geopolitical challenges, is progressing with product registration and online sales. Vinay Jamwal, Financial Advisor, added that the company operates at 67-68% capacity utilization, with potential for increased production.

Q: What steps have been taken to increase domestic sales? A: Vaibhav Munjal, Chief Marketing Officer, highlighted the expansion of the distribution network into tier 2 and tier 3 cities, strengthening the sales team, and diversifying the product portfolio. Despite initial challenges, domestic sales have picked up in the latter half of the year.

Q: How is the Oradox business performing, and what are the future plans for 3D printing? A: Dr. Sai Kalyan noted that Oradox faced a 2% sales decline due to export challenges but expects recovery with new product launches. In 3D printing, the company is ahead of competitors, with a 40% revenue increase in resins and plans for an indigenous 3D printer by 2028.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.